Luna Prieto Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luna Prieto Garcia has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Erik Sjögren
Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden
5 shared publications - Hans Lennernäs
Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development Uppsala University Uppsala Sweden
4 shared publications Christine Ahlström
DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden
3 shared publications- Anna Vildhede
DMPK & BBA, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden
2 shared publications - Christine Ahlström
DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2 shared publications - Pär Nordell
DMPK, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 1-11
Integrated Physiologically-based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 2: MIDD and MIPD Applications
The conventional strategy of prescribing the same dosage to all patients can result in suboptimal efficacy and safety. This is particularly true when considering drug-gene interactions (DGIs), drug-drug interactions (DDIs), or in individuals with compromised organ function. Precision medicine, which aims to tailor drug regimens based on individual patient characteristics, offers a promising alternative by focusing on drug disposition, efficacy, and safety. However, clinical trials face ethical and practical challenges and cannot cover all real-world patient scenarios. Thus, physiological based pharmacokinetic (PBPK) modeling offers a unique framework for enhancing model-informed drug development (MIDD) and precision dosing (MIPD). Despite this, most PBPK applications primarily assess drug pharmacokinetics without evaluating efficacy or safety outcomes. This limits the full potential of mechanistic models. In this study we used integrated PBPK, Quantitative Systems Pharmacology (QSP), and toxicology models to predict risks in scenarios like DGIs, DDIs, and varied renal impairment by simultaneously assessing drug PK, pharmacological effect, and toxicity. The findings underscore the importance of considering pharmacological effects and myotoxicity risks, which differed from changes seen in plasma exposure. This study demonstrates the value of PBPK-QSP models in guiding dose adjustments to optimize the efficacy and safety balance in target patient populations, showcasing their strength in MIDD and MIPD strategies. Graphical Abstract
- 31 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 28 (1) , 1-11
Open AccessIntegrated Physiologically-based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 2: MIDD and MIPD Applications
The conventional strategy of prescribing the same dosage to all patients can result in suboptimal efficacy and safety. This is particularly true when considering drug-gene interactions (DGIs), drug-drug interactions (DDIs), or in individuals with compromised organ function. Precision medicine, which aims to tailor drug regimens based on individual patient characteristics, offers a promising alternative by focusing on drug disposition, efficacy, and safety. However, clinical trials face ethical and practical challenges and cannot cover all real-world patient scenarios. Thus, physiological based pharmacokinetic (PBPK) modeling offers a unique framework for enhancing model-informed drug development (MIDD) and precision dosing (MIPD). Despite this, most PBPK applications primarily assess drug pharmacokinetics without evaluating efficacy or safety outcomes. This limits the full potential of mechanistic models. In this study we used integrated PBPK, Quantitative Systems Pharmacology (QSP), and toxicology models to predict risks in scenarios like DGIs, DDIs, and varied renal impairment by simultaneously assessing drug PK, pharmacological effect, and toxicity. The findings underscore the importance of considering pharmacological effects and myotoxicity risks, which differed from changes seen in plasma exposure. This study demonstrates the value of PBPK-QSP models in guiding dose adjustments to optimize the efficacy and safety balance in target patient populations, showcasing their strength in MIDD and MIPD strategies. Graphical Abstract
- Open Access
- 6 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-13
Integrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation
It is important to understand the key factors affecting the pharmacokinetics (PK), pharmacological response and toxicity of a drug to ensure clinical therapeutic efficacy and safety across disease populations. Traditionally, label dose-adjustment recommendations for patient populations are based on drug plasma concentrations. However, plasma PK may not be an appropriate surrogate for response and/or toxicity for drugs like statins with intracellular targets and tissue distribution influenced by membrane transporters. This study presents the integration of a physiologically-based pharmacokinetic model with a quantitative systems pharmacology and toxicology (PBPK-QSP-TOX) model for statins in patients with normal kidney function and in different stages of chronic kidney disease (CKD). The QSP model was informed by 2753 measurements of circulating LDL concentrations in 1147 patients (NCT00654537). The TOX model was informed by a meta-analysis of creatine kinase elevation incidence per statin dose in 30 clinical studies (49,284 patients). The CKD populations accounted for disease related changes to 1) anatomy and physiology, 2) drug enzymes and transporters expression and 3) lipoprotein metabolism. This study provides a qualified PBPK-QSP-TOX model for statins that accurately describe plasma concentration–time profiles, lipid-lowering effect and myotoxicity risk over investigated dose range for patients with normal kidney function and varying degree of CKD. Graphical Abstract
- 6 October 2025
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (6) , 1-13
Open AccessIntegrated Physiologically-Based Pharmacokinetic Model with a Quantitative Systems Pharmacology and Toxicology Model for Statins in Disease Population. Part 1: Model Development and Validation
It is important to understand the key factors affecting the pharmacokinetics (PK), pharmacological response and toxicity of a drug to ensure clinical therapeutic efficacy and safety across disease populations. Traditionally, label dose-adjustment recommendations for patient populations are based on drug plasma concentrations. However, plasma PK may not be an appropriate surrogate for response and/or toxicity for drugs like statins with intracellular targets and tissue distribution influenced by membrane transporters. This study presents the integration of a physiologically-based pharmacokinetic model with a quantitative systems pharmacology and toxicology (PBPK-QSP-TOX) model for statins in patients with normal kidney function and in different stages of chronic kidney disease (CKD). The QSP model was informed by 2753 measurements of circulating LDL concentrations in 1147 patients (NCT00654537). The TOX model was informed by a meta-analysis of creatine kinase elevation incidence per statin dose in 30 clinical studies (49,284 patients). The CKD populations accounted for disease related changes to 1) anatomy and physiology, 2) drug enzymes and transporters expression and 3) lipoprotein metabolism. This study provides a qualified PBPK-QSP-TOX model for statins that accurately describe plasma concentration–time profiles, lipid-lowering effect and myotoxicity risk over investigated dose range for patients with normal kidney function and varying degree of CKD. Graphical Abstract
- Open Access
- 4 April 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (6) , 1029-1043
Physiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins
Statins are used to reduce liver cholesterol levels but also carry a dose‐related risk of skeletal muscle toxicity. Concentrations of statins in plasma are often used to assess efficacy and safety, but because statins are substrates of membrane transporters that are present in diverse tissues, local differences in intracellular tissue concentrations cannot be ruled out. Thus, plasma concentration may not be an adequate indicator of efficacy and toxicity. To bridge this gap, we used physiologically based pharmacokinetic (PBPK) modeling to predict intracellular concentrations of statins. Quantitative data on transporter clearance were scaled from in vitro to in vivo conditions by integrating targeted proteomics and transporter kinetics data. The developed PBPK models, informed by proteomics, suggested that organic anion–transporting polypeptide 2B1 (OATP2B1) and multidrug resistance–associated protein 1 (MRP1) play a pivotal role in the distribution of statins in muscle. Using these PBPK models, we were able to predict the impact of alterations in transporter function due to genotype or drug–drug interactions on statin systemic concentrations and exposure in liver and muscle. These results underscore the potential of proteomics‐guided PBPK modeling to scale transporter clearance from in vitro data to real‐world implications. It is important to evaluate the role of drug transporters when predicting tissue exposure associated with on‐ and off‐target effects.
- 4 April 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (6) , 1029-1043
Open AccessPhysiologically based pharmacokinetics modeling and transporter proteomics to predict systemic and local liver and muscle disposition of statins
Statins are used to reduce liver cholesterol levels but also carry a dose‐related risk of skeletal muscle toxicity. Concentrations of statins in plasma are often used to assess efficacy and safety, but because statins are substrates of membrane transporters that are present in diverse tissues, local differences in intracellular tissue concentrations cannot be ruled out. Thus, plasma concentration may not be an adequate indicator of efficacy and toxicity. To bridge this gap, we used physiologically based pharmacokinetic (PBPK) modeling to predict intracellular concentrations of statins. Quantitative data on transporter clearance were scaled from in vitro to in vivo conditions by integrating targeted proteomics and transporter kinetics data. The developed PBPK models, informed by proteomics, suggested that organic anion–transporting polypeptide 2B1 (OATP2B1) and multidrug resistance–associated protein 1 (MRP1) play a pivotal role in the distribution of statins in muscle. Using these PBPK models, we were able to predict the impact of alterations in transporter function due to genotype or drug–drug interactions on statin systemic concentrations and exposure in liver and muscle. These results underscore the potential of proteomics‐guided PBPK modeling to scale transporter clearance from in vitro data to real‐world implications. It is important to evaluate the role of drug transporters when predicting tissue exposure associated with on‐ and off‐target effects.
- Open Access
- 13 July 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 825-835
Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling
A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug–drug and disease (drug‐drug‐disease interaction (DDDI)). Physiologically‐based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients. However, the prediction confidence of PBPK modeling in the severe CKD population is still low when nonrenal pathways are involved. More mechanistic virtual disease population and robust validation cases are needed. To this end, we aimed to: (i) understand the implications of severe CKD on statins (atorvastatin, simvastatin, and rosuvastatin) pharmacokinetics (PK) and DDI; and (ii) predict untested clinical scenarios of statin‐roxadustat DDI risks in patients to guide suitable dose regimens. A novel virtual severe CKD population was developed incorporating the disease effect on both renal and nonrenal pathways. Drug and disease PBPK models underwent a four‐way validation. The verified PBPK models successfully predicted the altered PKs in patients for substrates and inhibitors and recovered the observed statin‐rifampicin DDIs in patients and the statin‐roxadustat DDIs in HVs within 1.25‐ and 2‐fold error. Further sensitivity analysis revealed that the severe CKD effect on statins PK is mainly mediated by hepatic BCRP for rosuvastatin and OATP1B1/3 for atorvastatin. The magnitude of statin‐roxadustat DDI in patients with severe CKD was predicted to be similar to that in HVs. PBPK‐guided suitable dose regimens were identified to minimize the risk of side effects or therapeutic failure of statins when co‐administered with roxadustat.
- 13 July 2023
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (4) , 825-835
Open AccessUnderstanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling
A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug–drug and disease (drug‐drug‐disease interaction (DDDI)). Physiologically‐based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients. However, the prediction confidence of PBPK modeling in the severe CKD population is still low when nonrenal pathways are involved. More mechanistic virtual disease population and robust validation cases are needed. To this end, we aimed to: (i) understand the implications of severe CKD on statins (atorvastatin, simvastatin, and rosuvastatin) pharmacokinetics (PK) and DDI; and (ii) predict untested clinical scenarios of statin‐roxadustat DDI risks in patients to guide suitable dose regimens. A novel virtual severe CKD population was developed incorporating the disease effect on both renal and nonrenal pathways. Drug and disease PBPK models underwent a four‐way validation. The verified PBPK models successfully predicted the altered PKs in patients for substrates and inhibitors and recovered the observed statin‐rifampicin DDIs in patients and the statin‐roxadustat DDIs in HVs within 1.25‐ and 2‐fold error. Further sensitivity analysis revealed that the severe CKD effect on statins PK is mainly mediated by hepatic BCRP for rosuvastatin and OATP1B1/3 for atorvastatin. The magnitude of statin‐roxadustat DDI in patients with severe CKD was predicted to be similar to that in HVs. PBPK‐guided suitable dose regimens were identified to minimize the risk of side effects or therapeutic failure of statins when co‐administered with roxadustat.
- Open Access
- 16 July 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (9) , 1194-1209
Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction
Physiologically‐based pharmacokinetic (PBPK) models have an important role in drug discovery/development and decision making in regulatory submissions. This is facilitated by predefined PBPK platforms with user‐friendly graphical interface, such as Simcyp and PK‐Sim. However, evaluations of platform differences and the potential implications for disposition‐related applications are still lacking. The aim of this study was to assess how PBPK model development, input parameters, and model output are affected by the selection of PBPK platform. This is exemplified via the establishment of simvastatin PBPK models (workflow, final models, and output) in PK‐Sim and Simcyp as representatives of established whole‐body PBPK platforms. The major finding was that the choice of PBPK platform influenced the model development strategy and the final model input parameters, however, the predictive performance of the simvastatin models was still comparable between the platforms. The main differences between the structure and implementation of Simcyp and PK‐Sim were found in the absorption and distribution models. Both platforms predicted equally well the observed simvastatin (lactone and acid) pharmacokinetics (20–80 mg), BCRP and OATP1B1 drug–gene interactions (DGIs), and drug–drug interactions (DDIs) when co‐administered with CYP3A4 and OATP1B1 inhibitors/inducers. This study illustrates that in‐depth knowledge of established PBPK platforms is needed to enable an assessment of the consequences of PBPK platform selection. Specifically, this work provides insights on software differences and potential implications when bridging PBPK knowledge between Simcyp and PK‐Sim users. Finally, it provides a simvastatin model implemented in both platforms for risk assessment of metabolism‐ and transporter‐mediated DGIs and DDIs.
- 16 July 2022
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (9) , 1194-1209
Open AccessDoes the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction
Physiologically‐based pharmacokinetic (PBPK) models have an important role in drug discovery/development and decision making in regulatory submissions. This is facilitated by predefined PBPK platforms with user‐friendly graphical interface, such as Simcyp and PK‐Sim. However, evaluations of platform differences and the potential implications for disposition‐related applications are still lacking. The aim of this study was to assess how PBPK model development, input parameters, and model output are affected by the selection of PBPK platform. This is exemplified via the establishment of simvastatin PBPK models (workflow, final models, and output) in PK‐Sim and Simcyp as representatives of established whole‐body PBPK platforms. The major finding was that the choice of PBPK platform influenced the model development strategy and the final model input parameters, however, the predictive performance of the simvastatin models was still comparable between the platforms. The main differences between the structure and implementation of Simcyp and PK‐Sim were found in the absorption and distribution models. Both platforms predicted equally well the observed simvastatin (lactone and acid) pharmacokinetics (20–80 mg), BCRP and OATP1B1 drug–gene interactions (DGIs), and drug–drug interactions (DDIs) when co‐administered with CYP3A4 and OATP1B1 inhibitors/inducers. This study illustrates that in‐depth knowledge of established PBPK platforms is needed to enable an assessment of the consequences of PBPK platform selection. Specifically, this work provides insights on software differences and potential implications when bridging PBPK knowledge between Simcyp and PK‐Sim users. Finally, it provides a simvastatin model implemented in both platforms for risk assessment of metabolism‐ and transporter‐mediated DGIs and DDIs.
- 1 October 2018
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (10) , 1420-1433
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions
Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a ′bottom-up′ approach is challenging. Not only due to complex saturable pharmacokinetics (PK) and presence of three metabolites exhibiting CYP3A4 inhibition, but also because discrepancies in reported in vitro data. The overall objective of this study is to provide a comprehensive mechanistic PBPK model for itraconazole to increase the confidence in its drug-drug interaction (DDI) predictions. To achieve this, key in vitro and in vivo data for itraconazole and its major metabolites were generated. This data was crucial to develop a novel ′bottom-up′ PBPK model in Simcyp® for itraconazole and two of its major metabolites: hydroxy- itraconazole (OH-ITZ) and keto-itraconazole (keto-ITZ). Performance of the model was validated using pre-specified acceptance criteria against different dosing regimens, formulations for 29 PK and DDI studies with midazolam and other CYP3A4 substrates. The main outcome is an accurate PBPK model that simultaneously predicts the PK profiles of itraconazole, OH-ITZ and keto-ITZ. In addition, DDI between midazolam and itraconazole were successfully predicted within a 2-fold error for all the studies. Prediction precision and bias of DDI expressed as geometric mean fold error were for the area under the concentration- time curve and peak concentration, 1.06 and 0.96, respectively. To conclude, in this paper a comprehensive dataset for itraconazole and its metabolites is provided that enables bottom-up mechanism based PBPK modeling. The presented model is applicable for studying the contribution from the metabolites and allows improved assessments of itraconazole DDI.
- 1 October 2018
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (10) , 1420-1433
Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions
Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a ′bottom-up′ approach is challenging. Not only due to complex saturable pharmacokinetics (PK) and presence of three metabolites exhibiting CYP3A4 inhibition, but also because discrepancies in reported in vitro data. The overall objective of this study is to provide a comprehensive mechanistic PBPK model for itraconazole to increase the confidence in its drug-drug interaction (DDI) predictions. To achieve this, key in vitro and in vivo data for itraconazole and its major metabolites were generated. This data was crucial to develop a novel ′bottom-up′ PBPK model in Simcyp® for itraconazole and two of its major metabolites: hydroxy- itraconazole (OH-ITZ) and keto-itraconazole (keto-ITZ). Performance of the model was validated using pre-specified acceptance criteria against different dosing regimens, formulations for 29 PK and DDI studies with midazolam and other CYP3A4 substrates. The main outcome is an accurate PBPK model that simultaneously predicts the PK profiles of itraconazole, OH-ITZ and keto-ITZ. In addition, DDI between midazolam and itraconazole were successfully predicted within a 2-fold error for all the studies. Prediction precision and bias of DDI expressed as geometric mean fold error were for the area under the concentration- time curve and peak concentration, 1.06 and 0.96, respectively. To conclude, in this paper a comprehensive dataset for itraconazole and its metabolites is provided that enables bottom-up mechanism based PBPK modeling. The presented model is applicable for studying the contribution from the metabolites and allows improved assessments of itraconazole DDI.